**Ethiopia**

**Population 2018**: 109 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>165 (116–223)</td>
<td>151 (107–204)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>7.6 (5.3–10)</td>
<td>7 (4.9–9.4)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>1.6 (1–2.2)</td>
<td>1.4 (0.96–2)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>24 (15–36)</td>
<td>22 (14–33)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.2 (1.5–3)</td>
<td>2 (1.4–2.8)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- New cases: 0.71% (0.62–0.8)
- Previously treated cases: 16% (14–17)

**TB case notifications, 2018**

- Total new and relapse: 113 613

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 69% (51–98)
- TB patients facing catastrophic total costs: 17% (9–25)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 0.71% (0.62–0.8)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 80%
  - New cases: 80%
  - Previously treated cases: 100%

**Laboratory-confirmed cases**

- MDR/RR-TB: 741, XDR-TB: 3
- Patients started on treatment: 360
  - MDR/RR-TB: 747, XDR-TB: 3

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 49%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 22% (20–24)

**TB financing, 2019**

- National TB budget (US$ millions): 94
- Funding source: 11% domestic, 29% international, 60% unfunded

---

© Ranges represent uncertainty intervals
°° MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
°°° Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-01-14  Data: www.who.int/tb/data